00:00:00Intro
00:00:08Episode
00:18:40Outro
ဤအပိုင်းအကြောင်း
This episode looks at new pressure points in lab medicine: payment reporting, LDT oversight, liquid biopsy expansion, supplier stability, and compliance risk.
PAMA reporting: CMS is collecting private-payer data for the Clinical Laboratory Fee Schedule, but Laboratory Economics reports CMS may not know exactly which labs qualify as “applicable laboratories.” That raises questions about data quality, enforcement, and future Medicare lab rates.
Enhancing CLIA Act of 2026: A new bill from Rep. Neal Dunn would keep LDT oversight centered in CLIA/CMS rather than FDA device regulation. It proposes a public LDT database, more transparency around validation and performance, third-party validity confirmation, centralized error reporting, and stronger CMS authority when LDT validity is questioned.
Guardant360 Liquid CDx: Guardant received FDA approval for an expanded liquid biopsy panel. The story highlights the growing role of blood-based genomic profiling in oncology, along with challenges around interpretation, limitations, and reimbursement.
Bio-Rad and Elliott: Elliott reportedly built a stake in Bio-Rad. For labs, this is a reminder that vendor strategy and financial pressure can affect reagents, QC materials, instruments, service, and validated workflows.
Key Takeaway
Labs are being asked to support payment policy, regulatory oversight, precision medicine, supply chains, and compliance systems. The big question: are the people designing these systems accounting for how labs actually work?
အင်္ဂလိပ်
အမေရိကန်ပြည်ထောင်စု
ဤအပိုင်းထဲတွင်
SHOW မှတ်စုများ 🔗
ကူးယူချက် 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
ပြီးခဲ့သည့် အပိုင်းများကို ရှာဖွေပါ
LabReflex ၏ ယခင်အပိုင်းများကို ရှာဖွေပါ
ဤ PODCAST တွင် အခြားသော အပိုင်းများ
(00:00) - Intro
(00:08) - Start
(00:08) - Welcome To LabReflex
(02:31) - Measles Outbreak And Preparedness
(10:07) - Enterprise Ready Clinical AI
(22:39) - Point Of Care Testing Ecosystem
(25:21) - Who Owns The AI Data
(29:08) - Lab Business And Future Growth
(31:33) - Outro
DMT Defined Defining what a DMT is and what it is not.
Summary The discussion focuses on defining Diagnostic Management Teams (DMTs) by emphasizing that a true DMT must be expert-driven, patient-specific, and aim to establish a single diagnosis in the context of the patient's illness. It contrasts …
Field Notes 1: UAMS and MLS Training
The challenge of staffing Medical Laboratory Science positions, particularly in rural areas, and a scalable solution for recruitment.
Summary There is a significant shortage of Medical Laboratory Science staff, especially in rural settings, which creates severe …
Workforce and AI in Laboratory Medicine
Summary The medical laboratory workforce faces a shortage compounded by retirements, requiring systemic changes in education. Guidance from CAP focuses on structuring case review to reduce interpretive errors. Furthermore, the integration of AI into lab medic…
# After the Cookout: Parasites, Pneumonia, and the Lab’s Summer Surge
## SummaryThe conversation covered outbreaks like Cyclosporiasis and Legionnaires Disease, showing how laboratory testing connects to public health investigations. It also discussed the need for better data integration within lab…
မသက်ဆိုင်ကြောင်းရှင်းလင်းချက်: ဤစာမျက်နှာပေါ်တွင် ထည့်သွင်းထားသော ပေါ့တ်ကာစ်နှင့် အနုပညာလက်ရာများသည် ၎င်း၏ပိုင်ရှင်၏ပိုင်ဆိုင်မှုဖြစ်သည့် Christopher Zahner, MD မှဖြစ်ပြီး Listen Notes, Inc နှင့် ဆက်နွှယ်ခြင်း သို့မဟုတ် ထောက်ခံထားခြင်းမရှိပါ။
ပြင်ဆင်ပါ
ပေါ့ဒ်ကတ်စ် ဒေတာဘေ့စ်ကို နောက်ဆုံးပေါ်အချိန်နှင့်တပြေးညီဖြစ်စေရန် ကူညီပေးသည့်အတွက် ကျေးဇူးတင်ပါသည်။
